Revelation Biosciences Inc. Announces Initiation of a Phase 2b Study to Assess Efficacy of Intranasal REVTx-99 for The Prevention of H3N2 Influenza

NEXT STORY
Codiak BioSciences to Present at the 4th Annual Evercore ISI HealthCONx Conference
PREV STORY
Lexipol’s Wellness App for First Responders Wins Innovation Award
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Aptevo Therapeutics and Alligator Bioscience Commence IND-Enabling Development Activities for New Bispecific Immunotherapy Candidate ALG.APV-527

Novel Bispecific Antibody Targeting Biological Pathway Implicated in Multiple Solid Tumor Indications SEATTLE and LUND, ...

author_avatar
NASDAQ Market News

Editas Medicine Announces First Quarter 2018 Results and Update

Expanded Celgene collaboration to drive lead oncology program in solid tumors Strengthened Board of ...

author_avatar
NASDAQ Market News

Long Term Safety Data Published on Cytori Technology for Breast Reconstruction After Oncologic Surgery & Radiation Therapy

SAN DIEGO, June 08, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) (“Cytori” or the ...

author_avatar
NASDAQ Market News